Td Asset Management Inc Arcus Biosciences, Inc. Transaction History

Td Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$16.97 - $22.03 $137,457 - $178,443	8,100 Added 52.6%	23,500 $477,000
Q1 2023 May 10, 2023	SELL	$15.96 - $23.15 $748,524 - $1.09 Million	-46,900 Reduced 75.28%	15,400 $280,000
Q4 2022 Feb 06, 2023	BUY	$19.7 - $35.71 $1.23 Million - $2.22 Million	62,300 New	62,300 $1.29 Million
Q1 2019 May 08, 2019	SELL	$8.95 - $12.49 $185,784 - $259,267	-20,758 Closed	0 $0
Q4 2018 Feb 01, 2019	SELL	$9.74 - $14.5 $19,509 - $29,043	-2,003 Reduced 8.8%	20,758 $224,000
Q3 2018 Nov 01, 2018	SELL	$10.88 - $14.95 $70,687 - $97,130	-6,497 Reduced 22.21%	22,761 $317,000
Q1 2018 May 11, 2018	BUY	$15.44 - $17.71 $451,743 - $518,159	29,258 New	29,258 $452,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.